Status:
COMPLETED
An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Non-Squamous Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This multicenter, observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in participants with locally advanced or metastatic adenocarcinoma non-small cell lung cancer and an ...
Eligibility Criteria
Inclusion
- Adult participants, \>/= 18 years of age
- Histologically or cytologically confirmed, locally advanced (Stage IIIb) or metastatic (Stage IV) adenocarcinoma non-small cell lung cancer
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Adequate hematologic, renal and liver function
- Participant initiating treatment with Tarceva according to the Summary of Product Characteristics
Exclusion
- Any contraindications to treatment with Tarceva according to the Summary of Product Characteristics and local label
- Any other malignancies within the previous 5 years, except for in situ carcinoma of the cervix and basal and squamous cell carcinoma of the skin
- Previous systemic anti-cancer treatment with HER1/EGFR inhibitor
Key Trial Info
Start Date :
May 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT01836133
Start Date
May 1 2013
End Date
January 1 2016
Last Update
May 4 2017
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Center of Serbia; Institute For Pulmology
Belgrade, Serbia, 11000
2
Institute for Oncology and Radiology of Serbia; Medical Oncology
Belgrade, Serbia, 11000
3
Military Medical Academy; Clinic for Pulmonology
Belgrade, Serbia, 11000
4
Institute for pulmonary diseases of Vojvodina
Kamenitz, Serbia, 21204